TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16825698

Group type: EXPERIMENTAL
Intervention: Maternal and infant vitamin A supplementation (400,000 IU for mothers, 50,000 IU for infants)
Number of subjects: 1592

Group type: COMPARATOR
Intervention: Mothers received vitamin A and infants received placebo
Number of subjects: 1592

Group type: COMPARATOR
Intervention: Mothers received placebo and infants received vitamin A
Number of subjects: 1592

Group type: COMPARATOR
Intervention: Mothers and infants received placebo
Number of subjects: 1592

Group type: EXPERIMENTAL
Intervention: Infant HIV infection
Number of subjects: 1592

Group type: EXPERIMENTAL
Intervention: Male sex and lower total body iron at birth
Number of subjects: 1592

Group type: EXPERIMENTAL
Intervention: Early infection, low maternal CD4+ lymphocyte count at recruitment, and frequent morbidity in HIV-positive infants
Number of subjects: 1592

Group type: EXPERIMENTAL
Intervention: Six-month plasma ferritin concentrations <12 microg/L in HIV-negative infants
Number of subjects: 1592

Group type: EXPERIMENTAL
Intervention: Maternal HIV infection
Number of subjects: 1592
Study: 12646297

Group type: EXPERIMENTAL
Intervention: Girls with earlier onset depression
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Boys with later onset depression
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Boys
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Comorbid disorders
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Age at depression onset
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Sex differences
Number of subjects: 87
Study: 11386628

Group type: EXPERIMENTAL
Intervention: Choice assessment process
Number of subjects: 136

Group type: COMPARATOR
Intervention: Fill-in-the-blank assessment process
Number of subjects: 136
Study: 9744143

Group type: EXPERIMENTAL
Intervention: Nisoldipine coat-core (CC) 20-40 mg once daily
Number of subjects: 229

Group type: COMPARATOR
Intervention: Felodipine 5-10 mg once daily
Number of subjects: 229
Study: 8038542

Group type: EXPERIMENTAL
Intervention: Patient Triggered Ventilation (PTV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Synchronous Intermittent Mandatory Ventilation (SIMV)
Number of subjects: 40
Study: 3176835

Group type: EXPERIMENTAL
Intervention: Subarachnoid (spinal) bupivacaine 0.5%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Epidural bupivacaine 0.5%
Number of subjects: 40
Study: 31130005

Group type: EXPERIMENTAL
Intervention: Group prenatal care with a behavioral sleep intervention (adapted from CBT-I online program Go! to Sleep®)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Group prenatal care (control)
Number of subjects: 53
Study: 30825342

Group type: EXPERIMENTAL
Intervention: Concurrent training (CT) intervention (resistance plus endurance training) for 20 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (non-exercise)
Number of subjects: 28
Study: 27955850

Group type: EXPERIMENTAL
Intervention: YES IN (Oral immunonutrition) administered for 8 days (3 sachets a day)
Number of subjects: 84

Group type: COMPARATOR
Intervention: NOT IN (no immunonutrition)
Number of subjects: 84

Group type: COMPARATOR
Intervention: NOT IN (no immunonutrition) in patients with rectal cancer
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: YES IN (Oral immunonutrition)
Number of subjects: 84
Study: 25349058

Group type: EXPERIMENTAL
Intervention: Paleolithic diet (PD)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Nordic nutrition recommendations (NNR)
Number of subjects: 49
Study: 24148035

Group type: EXPERIMENTAL
Intervention: Housing First intervention
Number of subjects: 497

Group type: COMPARATOR
Intervention: Treatment as usual (no housing or support)
Number of subjects: 497
Study: 20924595

Group type: EXPERIMENTAL
Intervention: Quercetin 150 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 19781408

Group type: EXPERIMENTAL
Intervention: Anacetrapib, 100 mg
Number of subjects: 1623

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1623
Study: 16423675

Group type: EXPERIMENTAL
Intervention: Mitral annulus motion (MAM)
Number of subjects: 408
Study: 15608806

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (exact details not specified)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Comparison with New Zealand population norms
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Modest weight loss intervention (exact details not specified)
Number of subjects: 250
Study: 11764221

Group type: EXPERIMENTAL
Intervention: Lateral wedge insole with elastic strapping of the subtalar joint (n = 46)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Traditional shoe insert wedge insole (n = 44)
Number of subjects: 90
Study: 9256553

Group type: EXPERIMENTAL
Intervention: Motivation-based HIV risk reduction intervention
Number of subjects: 102

Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 102
Study: 8440102

Group type: EXPERIMENTAL
Intervention: PEEP 10 cm H2O
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: PEEP 15 cm H2O
Number of subjects: 27

Group type: COMPARATOR
Intervention: PEEP 5 cm H2O
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: PEEP 20 cm H2O
Number of subjects: 27
Study: 31866170

Group type: EXPERIMENTAL
Intervention: Intervention (educational sessions and decision aid materials)
Number of subjects: 7635

Group type: COMPARATOR
Intervention: Control (standard care without intervention)
Number of subjects: 7635

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 7635

Group type: COMPARATOR
Intervention: Control
Number of subjects: 7635
Study: 31306056

Group type: EXPERIMENTAL
Intervention: %PC 38:3 concentration
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 839
Study: 28916311

Group type: EXPERIMENTAL
Intervention: Lenalidomide (5 mg daily, escalated to 15 mg if tolerated)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 89
Study: 24938453

Group type: EXPERIMENTAL
Intervention: 10% trichloroacetic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25% trichloroacetic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 0
Study: 23299649

Group type: EXPERIMENTAL
Intervention: Extraction of upper first molars and lightwire multibracket (MB) appliance
Number of subjects: 154

Group type: COMPARATOR
Intervention: Herbst-MB appliance
Number of subjects: 154
Study: 21447661

Group type: EXPERIMENTAL
Intervention: PRANDIAL strategy (n = 557)
Number of subjects: 1115

Group type: COMPARATOR
Intervention: BASAL strategy (n = 558)
Number of subjects: 1115
Study: 18375649

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0
Study: 17075913

Group type: EXPERIMENTAL
Intervention: Early interventions following trauma (initiated within the first 3 months after exposure)
Number of subjects: 0
Study: 12859326

Group type: EXPERIMENTAL
Intervention: Protease inhibitors (PIs) in the salvage regimen
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: >8 months on treatment
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Absolute decrease in plasma viral load (pVL)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Virological responders (> or =1 log10 HIV-1 RNA copies/mL decrease)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Virologically non-responders
Number of subjects: 159
Study: 11339007

Group type: EXPERIMENTAL
Intervention: Power Doppler ultrasonography (PD)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Lugol's iodine treatment
Number of subjects: 46
Study: 8970407

Group type: EXPERIMENTAL
Intervention: Metoprolol OROS 190 mg once daily
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Metoprolol OROS 285 mg once daily
Number of subjects: 65

Group type: COMPARATOR
Intervention: Metoprolol 100 mg 2 or 3 times daily
Number of subjects: 65
Study: 1290609

Group type: COMPARATOR
Intervention: Distilled H2O only (Control)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 100 ppm F-
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 250 ppm F-
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 500 ppm F-
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 1000 ppm F-
Number of subjects: 25
Study: 6373331

Group type: EXPERIMENTAL
Intervention: Topical 0.125% clonidine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fellow placebo-treated eyes
Number of subjects: 24
Study: 31537473

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (30-40 sessions, 100% oxygen, breathed at a pressure of 240-250 kPa, for 80-90 min daily)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 79
Study: 30052208

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.8 μg/kg/h)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Propofol (1.5 mg/kg/h)
Number of subjects: 50
Study: 27064889

Group type: EXPERIMENTAL
Intervention: Feedback respiratory exercise
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diaphragm respiratory exercise
Number of subjects: 30
Study: 23672209

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection with needle electromyographic guidance (Group A, 15 patients)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Botulinum toxin injection without electromyographic guidance (Group B, 12 patients)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 27
Study: 23135189

Group type: EXPERIMENTAL
Intervention: Flowable resin and self‐etching adhesive (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flowable resin and phosphate acid system (Group B)
Number of subjects: 0
Study: 21312293

Group type: EXPERIMENTAL
Intervention: Nicotine inhalers
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo inhalers
Number of subjects: 24
Study: 17666915

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg/day
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg/day
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg/day and Valsartan 80 mg/day (combination)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 15020512

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg/day for three weeks)
Number of subjects: 60
Study: 12518121

Group type: EXPERIMENTAL
Intervention: 1.5 million IU streptokinase (Group A)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 100 mg t-PA (Group B)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No thrombolytic therapy (Group C)
Number of subjects: 56
Study: 9690729

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg b.d. + Amoxycillin 500 mg t.d.s. for 2 weeks (Study 1)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.d. + Amoxycillin 1 g t.d.s. for 2 weeks (Study 2)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.d. + Amoxycillin 1 g t.d.s. for 2 weeks (Study 3)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Omeprazole monotherapy
Number of subjects: 182

Group type: COMPARATOR
Intervention: Amoxycillin monotherapy
Number of subjects: 182
Study: 8089770

Group type: COMPARATOR
Intervention: Water exercise (Veterans group, N = 27, exercising for 35.2 months on average)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Water exercise (Newcomers group, N = 40, exercising for 3-4 weeks)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Non-exercisers (N = 30)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Water exercise (Veterans group, N = 20)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Water exercise (general awareness of health and fitness)
Number of subjects: 97
Study: 2698566

Group type: EXPERIMENTAL
Intervention: Diltiazem 90 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diltiazem 180 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gallopamil 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gallopamil 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gallopamil 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine (Capsule) 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine (Capsule) 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine (Capsule) 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine (Tablet) 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine (Tablet) 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine (Tablet) 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiapamil 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiapamil 600 mg
Number of subjects: 0
Study: 1093655

Group type: EXPERIMENTAL
Intervention: Ampicillin, 500 mg, 4 times daily for 10 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole, 4 times daily for 10 days
Number of subjects: 40
Study: 31838002

Group type: EXPERIMENTAL
Intervention: Pradefovir 30 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pradefovir 60 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pradefovir 75 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pradefovir 90 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pradefovir 120 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Adefovir dipivoxil (ADV) 10 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg
Number of subjects: 51
Study: 30576013

Group type: EXPERIMENTAL
Intervention: Vildagliptin-metformin combination treatment
Number of subjects: 2001

Group type: COMPARATOR
Intervention: Metformin monotherapy (standard-of-care)
Number of subjects: 2001
Study: 28370361

Group type: EXPERIMENTAL
Intervention: Collagenated porcine bone plus cross‐linked collagen membrane
Number of subjects: 30

Group type: COMPARATOR
Intervention: Collagenated bovine bone plus non‐cross‐linked collagen membrane
Number of subjects: 30
Study: 26164709

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT) group (N = 19)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (CG) (N = 16)
Number of subjects: 27
Study: 23438853

Group type: EXPERIMENTAL
Intervention: Morphine (0.08mg/kg)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Pentazocine (0.5mg/kg)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 101
Study: 21094193

Group type: EXPERIMENTAL
Intervention: Ostracism (induced by a computerized ball-tossing game - Cyberball)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inclusion (control condition)
Number of subjects: 0
Study: 19877979

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 12
Study: 16946209

Group type: EXPERIMENTAL
Intervention: Prophylactic bilateral salpingo-oophorectomy (BSO)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 106
Study: 14696021

Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Valerian 500 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Valerian 1000 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 10933133

Group type: EXPERIMENTAL
Intervention: Glibenclamide from metformin/glibenclamide tablets
Number of subjects: 24
Study: 8733449

Group type: EXPERIMENTAL
Intervention: Ofloxacin eardrops
Number of subjects: 52

Group type: COMPARATOR
Intervention: Neomycin-polymyxin B-hydrocortisone eardrops
Number of subjects: 52
Study: 1415072

Group type: EXPERIMENTAL
Intervention: Cephalexin
Number of subjects: 525

Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 525
Study: 3921585

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (20 cm2 patch)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30888927

Group type: COMPARATOR
Intervention: Phosphoric acid etching for 15 seconds (G0 - control group)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Phosphoric acid etching for 30 seconds (G1)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ultrasound probe applied for 30 seconds (G2)
Number of subjects: 29
Study: 29295516

Group type: EXPERIMENTAL
Intervention: MedDiet + EVOO
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MedDiet + nuts
Number of subjects: 36

Group type: COMPARATOR
Intervention: Low-fat control group
Number of subjects: 36
Study: 26025216

Group type: EXPERIMENTAL
Intervention: Platelet function testing
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100

Group type: COMPARATOR
Intervention: Untested usual care
Number of subjects: 100
Study: 24400838

Group type: EXPERIMENTAL
Intervention: Two-day teacher training
Number of subjects: 193

Group type: COMPARATOR
Intervention: No teacher training (control)
Number of subjects: 193
Study: 22623413

Group type: EXPERIMENTAL
Intervention: Oral alanyl-glutamine (GLN) 25 g twice daily for 3 days preoperatively
Number of subjects: 14

Group type: COMPARATOR
Intervention: Maltodextrin (CONT)
Number of subjects: 14
Study: 18829141

Group type: EXPERIMENTAL
Intervention: Web-based learning
Number of subjects: 93

Group type: COMPARATOR
Intervention: Face-to-face learning
Number of subjects: 93
Study: 17514499

Group type: EXPERIMENTAL
Intervention: MF59‐adjuvanted subunit vaccine (Sub/MF59)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Conventional subunit vaccine (Subunit)
Number of subjects: 238
Study: 15600247

Group type: EXPERIMENTAL
Intervention: HCV‐AB68 and HCV‐AB65 (HepeX‐C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HCV‐AB68 (alone)
Number of subjects: 0
Study: 11436117

Group type: EXPERIMENTAL
Intervention: G‐CSF 6 microg/kg/day s.c.
Number of subjects: 156
Study: 9807988

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 1011

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1011
Study: 7544174

Group type: EXPERIMENTAL
Intervention: Alpha 1-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 alpha-reductase inhibitors
Number of subjects: 0
Study: 2527819

Group type: EXPERIMENTAL
Intervention: ANF infusion (0.75 pmol/kg/min for 3 hours)
Number of subjects: 6
Study: 1067398

Group type: EXPERIMENTAL
Intervention: Free autogenous gingival grafts placed on alveolar bone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Free autogenous gingival grafts placed on periosteum
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Free autogenous gingival grafts placed on alveolar bone and periosteum
Number of subjects: 60
Study: 31060491

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Calcitonin gene‐related peptide
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5

Group type: COMPARATOR
Intervention: 3.0 T MR angiography
Number of subjects: 5

Group type: COMPARATOR
Intervention: 7.0 T MR angiography
Number of subjects: 5

Group type: COMPARATOR
Intervention: QMra software
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: LAVA software
Number of subjects: 5
Study: 28287415

Group type: EXPERIMENTAL
Intervention: 30% Ahiflower oil + 70% high oleic sunflower oil
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 60% Ahiflower oil + 40% high oleic sunflower oil
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 100% Ahiflower oil
Number of subjects: 88

Group type: COMPARATOR
Intervention: 100% high oleic sunflower oil
Number of subjects: 88
Study: 25749010

Group type: EXPERIMENTAL
Intervention: Lateral wedge insoles
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control shoe
Number of subjects: 70
Study: 23648392

Group type: EXPERIMENTAL
Intervention: Need-based intervention (50g/day soy-protein-based nutritional supplement)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Need-based intervention
Number of subjects: 92
Study: 21710480

Group type: EXPERIMENTAL
Intervention: 1 ml butyl‐2‐cyanoacrylate tissue glue (Glubran(®))
Number of subjects: 302

Group type: COMPARATOR
Intervention: Absorbable polyglycolic acid 3/0 sutures (Dexon(®))
Number of subjects: 302
Study: 19628107

Group type: EXPERIMENTAL
Intervention: Time-divided supplementation regimen (TDR)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Time-focused supplementation regimen (TFR)
Number of subjects: 13
Study: 16431305

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 282

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg twice daily
Number of subjects: 282
Study: 15587751

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5 microg/day) and calcium (1000 mg/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Calcium (1000 mg/day) alone
Number of subjects: 70

Group type: COMPARATOR
Intervention: Healthy control group (30 healthy women)
Number of subjects: 70
Study: 11502785

Group type: EXPERIMENTAL
Intervention: GH administration (20 microg/kg BW)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Sex hormone administration (hormone replacement therapy in women, testosterone enanthate in men)
Number of subjects: 110

Group type: COMPARATOR
Intervention: GH administration
Number of subjects: 110

Group type: COMPARATOR
Intervention: GH + testosterone enanthate
Number of subjects: 110

Group type: COMPARATOR
Intervention: Testosterone enanthate
Number of subjects: 110

Group type: COMPARATOR
Intervention: GH administration, testosterone enanthate, GH + testosterone enanthate
Number of subjects: 110
Study: 9426995

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1 g (CIP1)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg b.i.d. for 1 day (CIP2)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg b.i.d. for 3 days (D)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 74
Study: 8296092

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR vaccine (5 x 10^9 FU)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (5 x 10^9 heat-killed E. Coli K12)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR vaccine
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 6342841

Group type: EXPERIMENTAL
Intervention: Propranolol, 160 mg/day
Number of subjects: 560

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 560